These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24689499)

  • 1. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease.
    Levesque BG; Greenberg GR; Zou G; Sandborn WJ; Singh S; Hauenstein S; Ohrmund L; Wong CJ; Stitt LW; Shackelton LM; King D; Lockton S; Ducharme J; Feagan BG
    Aliment Pharmacol Ther; 2014 May; 39(10):1126-35. PubMed ID: 24689499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
    Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
    Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.
    Roblin X; Marotte H; Leclerc M; Del Tedesco E; Phelip JM; Peyrin-Biroulet L; Paul S
    J Crohns Colitis; 2015 Jul; 9(7):525-31. PubMed ID: 25895875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
    Roblin X; Duru G; Williet N; Del Tedesco E; Cuilleron M; Jarlot C; Phelip JM; Boschetti G; Flourié B; Nancey S; Peyrin-Biroulet L; Paul S
    Inflamm Bowel Dis; 2017 Jan; 23(1):126-132. PubMed ID: 28002129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
    Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
    Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
    Vande Casteele N; Khanna R; Levesque BG; Stitt L; Zou GY; Singh S; Lockton S; Hauenstein S; Ohrmund L; Greenberg GR; Rutgeerts PJ; Gils A; Sandborn WJ; Vermeire S; Feagan BG
    Gut; 2015 Oct; 64(10):1539-45. PubMed ID: 25336114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
    Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
    Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.
    Cornillie F; Hanauer SB; Diamond RH; Wang J; Tang KL; Xu Z; Rutgeerts P; Vermeire S
    Gut; 2014 Nov; 63(11):1721-7. PubMed ID: 24474383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
    Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis.
    Colombel JF; Reinisch W; Mantzaris GJ; Kornbluth A; Rutgeerts P; Tang KL; Oortwijn A; Bevelander GS; Cornillie FJ; Sandborn WJ
    Aliment Pharmacol Ther; 2015 Apr; 41(8):734-46. PubMed ID: 25728587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease.
    Hibi T; Sakuraba A; Watanabe M; Motoya S; Ito H; Motegi K; Kinouchi Y; Takazoe M; Suzuki Y; Matsumoto T; Kawakami K; Matsumoto T; Hirata I; Tanaka S; Ashida T; Matsui T
    Inflamm Bowel Dis; 2012 Aug; 18(8):1480-7. PubMed ID: 21987418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H; Takahashi K; Fujimoto T; Bamba S; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
    Reinisch W; Wang Y; Oddens BJ; Link R
    Aliment Pharmacol Ther; 2012 Mar; 35(5):568-76. PubMed ID: 22251435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
    Gonczi L; Vegh Z; Golovics PA; Rutka M; Gecse KB; Bor R; Farkas K; Szamosi T; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Papp M; Patai Á; Salamon Á; Tóth GT; Vincze Á; Biro E; Lovasz BD; Kurti Z; Szepes Z; Molnár T; Lakatos PL
    J Crohns Colitis; 2017 Jun; 11(6):697-705. PubMed ID: 27838610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with short- and long-term outcomes of therapy for Crohn's disease.
    Reinisch W; Colombel JF; Sandborn WJ; Mantzaris GJ; Kornbluth A; Adedokun OJ; Miller M; Tang KL; Rutgeerts P; Cornillie F
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):539-547.e2. PubMed ID: 25245629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.